KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report)'s share price rose 8.7% during trading on Wednesday . The company traded as high as $10.59 and last traded at $10.63. Approximately 241,567 shares traded hands during mid-day trading, a decline of 18% from the average daily volume of 295,156 shares. The stock had previously closed at $9.78.
Analyst Ratings Changes
KALV has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Bank of America began coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They issued a "buy" rating and a $22.00 price objective on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. JMP Securities began coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an "outperform" rating and a $19.00 price objective on the stock. Finally, Citizens Jmp upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, KalVista Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $23.80.
View Our Latest Analysis on KalVista Pharmaceuticals
KalVista Pharmaceuticals Stock Down 5.7 %
The stock has a 50-day simple moving average of $8.87 and a two-hundred day simple moving average of $10.41. The firm has a market cap of $495.68 million, a PE ratio of -2.76 and a beta of 0.85.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.01. Research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.
Insider Buying and Selling at KalVista Pharmaceuticals
In related news, insider Paul K. Audhya sold 3,125 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the sale, the insider now directly owns 100,334 shares of the company's stock, valued at $985,279.88. This trade represents a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Venrock Healthcare Capital Par bought 43,707 shares of the business's stock in a transaction that occurred on Thursday, January 30th. The stock was acquired at an average cost of $8.76 per share, for a total transaction of $382,873.32. Following the completion of the purchase, the insider now directly owns 4,986,480 shares of the company's stock, valued at $43,681,564.80. The trade was a 0.88 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 236,055 shares of company stock worth $2,162,146 and have sold 18,043 shares worth $176,758. Company insiders own 10.50% of the company's stock.
Institutional Trading of KalVista Pharmaceuticals
Several large investors have recently bought and sold shares of KALV. SG Americas Securities LLC bought a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at approximately $153,000. China Universal Asset Management Co. Ltd. raised its holdings in KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company's stock worth $96,000 after acquiring an additional 3,328 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its holdings in KalVista Pharmaceuticals by 23.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company's stock worth $7,538,000 after acquiring an additional 121,615 shares during the last quarter. Emerald Advisers LLC raised its stake in KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company's stock valued at $9,681,000 after buying an additional 192,091 shares during the last quarter. Finally, Quest Partners LLC purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $175,000.
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Read More
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
